xl092
xl092: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: EXELIXIS, INC. (EXEL)
Development Pipeline (1)
| Company | Phase |
|---|---|
| EXELIXIS, INC. (EXEL) | Phase 3 |
Clinical Trials (1)
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Frequently asked questions
Who is developing xl092?
xl092 is being developed by EXELIXIS, INC..
How many clinical trials involve xl092?
BioSniper tracks 1 clinical trial involving xl092.
Analyze EXELIXIS, INC. & xl092 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company